Press Release

23 December 2021

Lipigon and HitGen extend collaboration agreement on dyslipidemia project

Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.
05 November 2021

HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning

Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.
01 November 2021

Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS

Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.
29 October 2021

Infographic|HitGen FY2021 Q3 Report

Infographic|HitGen FY2021 Q3 Report
02 September 2021

Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery

CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.
31 August 2021

Infographic | HitGen FY2021 Mid-term Report

HitGen FY2021 Mid-term Report
10 June 2021

Vernalis, a fully owned subsidiary of HitGen Inc., and Servier achieve two milestones in their oncology drug discovery collaboration

Chengdu, China, 10 June 2021 – Vernalis, a fully owned subsidiary of HitGen Inc., and Servier are pleased to announce the achievement of one research and one pre-clinical milestone in their oncology drug discovery collaboration, triggering undisclosed milestone payments to Vernalis.
27 May 2021

Available now! Whitepaper: Advancing Drug Discovery through DNA Encoded Library Technology!

CHENGDU, China, May 27th, 2021 HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery community with an in depth dive of DEL technology and stimulate innovation in the field by describing HitGen’s experiences and knowledges on DEL design, synthesis, screening and expanded applications.
24 May 2021

Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, May 24th, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc.
13 May 2021

Coming Soon! Whitepaper: Advancing Drug Discovery through DNA-Encoded Library Technology！

Since its concept was conceived in 1992, DNA-encoded chemical libraries (DELs) have evolved into a valuable technology for hit identification in drug discovery.

News

Press Release

Thanks for reading!